2023 World Conference on Lung Cancer (Posters)-EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC

EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study compared the efficacy of entrectinib and crizotinib as first-line therapies for Asian patients with ROS1 fusion-positive advanced NSCLC. It used individual patient-level data from trials of entrectinib and aggregated data from a crizotinib trial to analyze the outcomes. The study aimed to provide comparative evidence to assist healthcare professionals in making treatment decisions for Asian patients with ROS1 NSCLC.<br /><br />The analysis showed a trend for better survival outcomes with entrectinib compared to crizotinib in Asian patients with ROS1 NSCLC. The median progression-free survival (PFS) was 39.4 months in the entrectinib cohort and 15.9 months in the crizotinib cohort. The hazard ratio (HR) for PFS was 0.688, suggesting a potential benefit of entrectinib. The median overall survival (OS) was not reached in the entrectinib cohort and was 44.2 months in the crizotinib cohort, with an HR of 0.662.<br /><br />The study used propensity score matching and weighting to balance the baseline characteristics of the two treatment groups. However, the effective sample size of the entrectinib cohort was relatively small, and there may have been hidden unmeasured prognostic factors or effect modifiers that could have influenced the results.<br /><br />This research provides valuable insights into the comparative efficacy of entrectinib and crizotinib in Asian patients with ROS1 NSCLC. The findings suggest that entrectinib may be a more favorable treatment option, but further research with larger sample sizes and consideration of other factors is needed to confirm these results. These findings may assist healthcare stakeholders in making more informed treatment decisions for Asian patients with ROS1 NSCLC. The study was sponsored by Shanghai Roche Pharmaceuticals Ltd.<br /><br />The authors disclosed their affiliations and potential conflicts of interest. The first author can be contacted via email for further information.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

efficacy

entrectinib

crizotinib

Asian patients

ROS1 fusion-positive NSCLC

progression-free survival

overall survival

treatment decisions

comparative efficacy

healthcare stakeholders